J F Merola1,2, T Li3, W-Q Li4, E Cho3,4,5, A A Qureshi3,4,5. 1. Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA. 2. Division of Rheumatology, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA. 3. Channing Division of Network Medicine, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA. 4. Department of Dermatology, Alpert School of Medicine, Brown University, Providence, RI, USA. 5. Department of Epidemiology, School of Public Health, Brown University, Providence, RI, USA.
Abstract
BACKGROUND: We present the largest set of US prevalence data for psoriasis to date, obtained from three prospective cohort studies describing validated clinical phenotypes of psoriasis, including novel data about the prevalence of inverse (intertriginous) psoriasis in these groups. Nonplaque psoriasis phenotypes have been largely unmeasured in observational and interventional studies, and this has led to an under-recognition of this aspect of psoriatic disease. AIM: To describe the prevalence of nonplaque psoriasis phenotypes in a large prospective cohort. METHODS: We included 3179 women and 646 men in the analysis. Participants in the Nurses Health Study (NHS) and Health Professionals Follow-up Study (HPFS) with physician-diagnosed psoriasis completed a validated, self-administered questionnaire to assess plaque and nonplaque subsets of psoriasis. RESULTS: Psoriasis phenotypes were as follows: plaque 55%, scalp 52%, palmar-plantar 14%, nail 23% and inverse 21% in the NHS (n = 1604); plaque 60%, scalp 56%, palmar-plantar 16%, nail 27% and inverse 24% in the second NHS study (NHS II) (n = 1575); and plaque 55%, scalp 45%, palmar-plantar 12%, nail 27% and inverse 30% in the HPFS (n = 646). Scalp, nail, palmar-plantar and inverse disease represent highly prevalent phenotypes of psoriasis in the USA. CONCLUSION: Scalp, nail, palmar-plantar and inverse disease represent highly prevalent phenotypes of psoriasis.
BACKGROUND: We present the largest set of US prevalence data for psoriasis to date, obtained from three prospective cohort studies describing validated clinical phenotypes of psoriasis, including novel data about the prevalence of inverse (intertriginous) psoriasis in these groups. Nonplaque psoriasis phenotypes have been largely unmeasured in observational and interventional studies, and this has led to an under-recognition of this aspect of psoriatic disease. AIM: To describe the prevalence of nonplaque psoriasis phenotypes in a large prospective cohort. METHODS: We included 3179 women and 646 men in the analysis. Participants in the Nurses Health Study (NHS) and Health Professionals Follow-up Study (HPFS) with physician-diagnosed psoriasis completed a validated, self-administered questionnaire to assess plaque and nonplaque subsets of psoriasis. RESULTS:Psoriasis phenotypes were as follows: plaque 55%, scalp 52%, palmar-plantar 14%, nail 23% and inverse 21% in the NHS (n = 1604); plaque 60%, scalp 56%, palmar-plantar 16%, nail 27% and inverse 24% in the second NHS study (NHS II) (n = 1575); and plaque 55%, scalp 45%, palmar-plantar 12%, nail 27% and inverse 30% in the HPFS (n = 646). Scalp, nail, palmar-plantar and inverse disease represent highly prevalent phenotypes of psoriasis in the USA. CONCLUSION: Scalp, nail, palmar-plantar and inverse disease represent highly prevalent phenotypes of psoriasis.
Authors: C E M Griffiths; E Christophers; J N W N Barker; R J G Chalmers; S Chimenti; G G Krueger; C Leonardi; A Menter; J-P Ortonne; L Fry Journal: Br J Dermatol Date: 2007-02 Impact factor: 9.302
Authors: Floranne C Wilson; Murat Icen; Cynthia S Crowson; Marian T McEvoy; Sherine E Gabriel; Hilal Maradit Kremers Journal: Arthritis Rheum Date: 2009-02-15
Authors: Isabelle M Sanchez; Lindsey Shankle; Marilyn T Wan; Ladan Afifi; Jashin J Wu; Frank Doris; Alisha Bridges; Marc Boas; Brian Lafoy; Sarah Truman; Ana-Maria Orbai; Junko Takeshita; Joel M Gelfand; April W Armstrong; Michael P Siegel; Wilson Liao Journal: Dermatol Ther (Heidelb) Date: 2018-06-06
Authors: Jesus Miguens Blanco; Federica Borghese; Neil McHugh; Peter Kelleher; Raj Sengupta; Julian R Marchesi; Sonya Abraham Journal: BMC Rheumatol Date: 2020-11-10